{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04530630",
      "orgStudyIdInfo": {
        "id": "20-01021384"
      },
      "organization": {
        "fullName": "Weill Medical College of Cornell University",
        "class": "OTHER"
      },
      "briefTitle": "Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant",
      "officialTitle": "The Efficacy, Safety, and Tolerability of Switching to a Bictegravir (BIC)/Emtricitabine(FTC)/Tenofovir Alafenamide (TAF) Regimen in Virally Suppressed Human Immunodeficiency Viruses (HIV)-Positive Patients Post-Renal Transplant"
    },
    "statusModule": {
      "statusVerifiedDate": "2025-07",
      "overallStatus": "COMPLETED",
      "expandedAccessInfo": {
        "hasExpandedAccess": false
      },
      "startDateStruct": {
        "date": "2020-11-09",
        "type": "ACTUAL"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-08-28",
        "type": "ACTUAL"
      },
      "completionDateStruct": {
        "date": "2024-08-28",
        "type": "ACTUAL"
      },
      "studyFirstSubmitDate": "2020-08-24",
      "studyFirstSubmitQcDate": "2020-08-24",
      "studyFirstPostDateStruct": {
        "date": "2020-08-28",
        "type": "ACTUAL"
      },
      "resultsFirstSubmitDate": "2025-06-27",
      "resultsFirstSubmitQcDate": "2025-07-25",
      "resultsFirstPostDateStruct": {
        "date": "2025-08-12",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2025-07-25",
      "lastUpdatePostDateStruct": {
        "date": "2025-08-12",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "Weill Medical College of Cornell University",
        "class": "OTHER"
      },
      "collaborators": [
        {
          "name": "Gilead Sciences",
          "class": "INDUSTRY"
        }
      ]
    },
    "oversightModule": {
      "oversightHasDmc": false,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false,
      "isUsExport": false
    },
    "descriptionModule": {
      "briefSummary": "This is an open-label study, where participants will be switched from their current HIV medication to the study drug, BIC/F/TAF. Open-label means both the investigator and the participant will know what drug will be given. Participants will be followed for 48 weeks in order to monitor the efficacy, safety and tolerability of BIC/F/TAF. The investigator hypothesizes that BIC/F/TAF will be an important addition to the management of HIV-positive post renal transplant patients, especially since it is a one pill daily dosing regimen, thereby decreasing the pill burden in this population."
    },
    "conditionsModule": {
      "conditions": [
        "HIV Infections",
        "Renal Transplant Rejection"
      ],
      "keywords": [
        "HIV Positive",
        "Post Renal Transplant",
        "Bictegravir/Emtricitabine/Tenofovir Alafenamide",
        "Antiretroviral",
        "Biktarvy"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "designInfo": {
        "allocation": "NA",
        "interventionModel": "SINGLE_GROUP",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "NONE"
        }
      },
      "enrollmentInfo": {
        "count": 20,
        "type": "ACTUAL"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
          "type": "EXPERIMENTAL",
          "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food.",
          "interventionNames": [
            "Drug: BIC/F/TAF 50Mg-200Mg-25Mg Tablet"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "BIC/F/TAF 50Mg-200Mg-25Mg Tablet",
          "description": "A three-drug fixed dose combination tablet containing 50mg of bictegravir, 200mg of emtricitabine, and 25mg of tenofovir alafenamide.",
          "armGroupLabels": [
            "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)"
          ],
          "otherNames": [
            "Biktarvy"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "Number of Subjects With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies/ml",
          "description": "HIV viral loads will be obtained from lab reports.",
          "timeFrame": "Up to week 48 (End of Study)"
        },
        {
          "measure": "Safety (Tolerability) as Measured by the Number of Subjects Who Had a Serious Adverse Event (SAE)",
          "timeFrame": "Up to week 48 (End of study)"
        },
        {
          "measure": "Intracellular TAF Levels as Measured by Dried Blood Spot",
          "description": "Fmol/punch refers to the concentration of a substance, measured in femtomoles per a specific size of a dried blood spot (DBS) punch.",
          "timeFrame": "12 weeks"
        },
        {
          "measure": "Intracellular TAF Levels as Measured by Peripheral Blood Mononuclear Cells (PBMCs)",
          "description": "pmol/10\\^6 cells refers to the amount of a particular substance (in picomoles) per one million cells",
          "timeFrame": "12 weeks"
        },
        {
          "measure": "Renal Function as Measured by Blood Urea Nitrogen (BUN)",
          "timeFrame": "24 weeks, 48 weeks (End of study)"
        },
        {
          "measure": "Renal Function as Measured by Creatinine",
          "timeFrame": "24 weeks, 48 weeks (End of study)"
        },
        {
          "measure": "Renal Function as Measured by Creatinine Clearance",
          "timeFrame": "24 weeks, 48 weeks (End of study)"
        },
        {
          "measure": "Renal Function as Measured by Estimated Glomerular Filtration Rate (eGFR)",
          "timeFrame": "24 weeks, 48 weeks (End of study)"
        },
        {
          "measure": "Tacrolimus Levels",
          "timeFrame": "12 weeks, 24 weeks, 48 weeks (End of study)"
        }
      ],
      "secondaryOutcomes": [
        {
          "measure": "Change From Baseline CD4+ T Lymphocyte Numbers Post Renal Transplant",
          "description": "Number of CD4+ T lymphocyte counts will be obtained from lab reports",
          "timeFrame": "Day 1 (Baseline), Week 4, Week 12, Week 24, Week 36, Week 48 (End of study)"
        },
        {
          "measure": "Change From Baseline CD4+ T Lymphocyte Percentages Post Renal Transplant",
          "description": "CD4+ T lymphocyte percentages will be obtained from lab reports",
          "timeFrame": "Day 1 (Baseline), Week 4, Week 12, Week 24, Week 36, Week 48 (End of study)"
        },
        {
          "measure": "Number of Subjects With Rejection of the Kidney Transplant, Post Renal Transplant",
          "description": "Data for kidney graft rejection will be extracted from biopsy confirmed rejections.",
          "timeFrame": "up to 48 weeks (End of study)"
        },
        {
          "measure": "Participant Satisfaction With Reduced Pill Burden and Adverse Events (Tolerability) Measured by the Health-related Quality of Life Questionnaire",
          "description": "Satisfaction will be measured by the self-reporting health-related quality of life questionnaire ranging from 0 to 6 with higher scores indicating greater satisfaction with Biktarvy.",
          "timeFrame": "Week 24, Week 48 (End of study)"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* At least 18 years old on day of signing informed consent\n* Positive for human immunodeficiency virus (HIV)\n* Received a previous renal transplant\n* Must have controlled HIV infection for at least 3 months prior to enrollment\n\nExclusion Criteria:\n\n* Received a kidney from a donor who was HIV positive (unless a false positive)\n* Currently taking BIC/F/TAF for treatment of HIV\n* Has allergies to any of the HIV medications in BIC/F/TAF (bictegravir, emtricitabine, or tenofovir alafenamide)\n* Currently taking dofetilide or rifampin\n* Is pregnant or breastfeeding",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "overallOfficials": [
        {
          "name": "Catherine B Small, MD",
          "affiliation": "Weill Medical College of Cornell University",
          "role": "PRINCIPAL_INVESTIGATOR"
        }
      ],
      "locations": [
        {
          "facility": "Weill Cornell Medicine",
          "city": "New York",
          "state": "New York",
          "zip": "10065",
          "country": "United States",
          "geoPoint": {
            "lat": 40.71427,
            "lon": -74.00597
          }
        }
      ]
    },
    "referencesModule": {
      "references": [
        {
          "pmid": "29925489",
          "type": "BACKGROUND",
          "citation": "Molina JM, Ward D, Brar I, Mills A, Stellbrink HJ, Lopez-Cortes L, Ruane P, Podzamczer D, Brinson C, Custodio J, Liu H, Andreatta K, Martin H, Cheng A, Quirk E. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV. 2018 Jul;5(7):e357-e365. doi: 10.1016/S2352-3018(18)30092-4. Epub 2018 Jun 18."
        },
        {
          "pmid": "28867497",
          "type": "BACKGROUND",
          "citation": "Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31."
        },
        {
          "pmid": "28219610",
          "type": "BACKGROUND",
          "citation": "Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017 Apr;4(4):e154-e160. doi: 10.1016/S2352-3018(17)30016-4. Epub 2017 Feb 15."
        },
        {
          "pmid": "28993180",
          "type": "BACKGROUND",
          "citation": "Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E, Hufkens V, Petrovic R, Vanveggel S, Opsomer M; EMERALD study group. Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. Lancet HIV. 2018 Jan;5(1):e23-e34. doi: 10.1016/S2352-3018(17)30179-0. Epub 2017 Oct 6."
        },
        {
          "pmid": "26627107",
          "type": "BACKGROUND",
          "citation": "Pozniak A, Arribas JR, Gathe J, Gupta SK, Post FA, Bloch M, Avihingsanon A, Crofoot G, Benson P, Lichtenstein K, Ramgopal M, Chetchotisakd P, Custodio JM, Abram ME, Wei X, Cheng A, McCallister S, SenGupta D, Fordyce MW; GS-US-292-0112 Study Team. Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study. J Acquir Immune Defic Syndr. 2016 Apr 15;71(5):530-7. doi: 10.1097/QAI.0000000000000908."
        },
        {
          "pmid": "30460547",
          "type": "BACKGROUND",
          "citation": "Deeks ED. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection. Drugs. 2018 Nov;78(17):1817-1828. doi: 10.1007/s40265-018-1010-7."
        },
        {
          "type": "BACKGROUND",
          "citation": "Eron JJ, Lelievre J-D, Kalayjian R, Slim J, et al. Safety and Efficacy of E/C/F/TAF in HIV-Infected Adults on Chronic Hemodialysis (Abstract, poster 732 presented at CROI 2018)."
        },
        {
          "pmid": "21083386",
          "type": "BACKGROUND",
          "citation": "Stock PG, Barin B, Murphy B, Hanto D, Diego JM, Light J, Davis C, Blumberg E, Simon D, Subramanian A, Millis JM, Lyon GM, Brayman K, Slakey D, Shapiro R, Melancon J, Jacobson JM, Stosor V, Olson JL, Stablein DM, Roland ME. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010 Nov 18;363(21):2004-14. doi: 10.1056/NEJMoa1001197."
        },
        {
          "pmid": "25791727",
          "type": "BACKGROUND",
          "citation": "Locke JE, Mehta S, Reed RD, MacLennan P, Massie A, Nellore A, Durand C, Segev DL. A National Study of Outcomes among HIV-Infected Kidney Transplant Recipients. J Am Soc Nephrol. 2015 Sep;26(9):2222-9. doi: 10.1681/ASN.2014070726. Epub 2015 Mar 19."
        },
        {
          "pmid": "25896688",
          "type": "BACKGROUND",
          "citation": "Gunawardana M, Remedios-Chan M, Miller CS, Fanter R, Yang F, Marzinke MA, Hendrix CW, Beliveau M, Moss JA, Smith TJ, Baum MM. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis. Antimicrob Agents Chemother. 2015 Jul;59(7):3913-9. doi: 10.1128/AAC.00656-15. Epub 2015 Apr 20."
        },
        {
          "pmid": "28099191",
          "type": "BACKGROUND",
          "citation": "Kraft JC, McConnachie LA, Koehn J, Kinman L, Collins C, Shen DD, Collier AC, Ho RJ. Long-acting combination anti-HIV drug suspension enhances and sustains higher drug levels in lymph node cells than in blood cells and plasma. AIDS. 2017 Mar 27;31(6):765-770. doi: 10.1097/QAD.0000000000001405."
        },
        {
          "pmid": "30958667",
          "type": "BACKGROUND",
          "citation": "Pharmacoeconomic Review Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) (Biktarvy): (Gilead Sciences Canada, Inc.): Indication: A complete regimen for the treatment of HIV-1 infection in adults with no known substitution associated with resistance the individual components of Biktarvy [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Oct. Available from http://www.ncbi.nlm.nih.gov/books/NBK539546/"
        },
        {
          "pmid": "22935078",
          "type": "BACKGROUND",
          "citation": "Castillo-Mancilla JR, Zheng JH, Rower JE, Meditz A, Gardner EM, Predhomme J, Fernandez C, Langness J, Kiser JJ, Bushman LR, Anderson PL. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90. doi: 10.1089/AID.2012.0089. Epub 2012 Oct 10."
        },
        {
          "pmid": "27572401",
          "type": "BACKGROUND",
          "citation": "Castillo-Mancilla J, Seifert S, Campbell K, Coleman S, McAllister K, Zheng JH, Gardner EM, Liu A, Glidden DV, Grant R, Hosek S, Wilson CM, Bushman LR, MaWhinney S, Anderson PL. Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing. Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697. doi: 10.1128/AAC.01017-16. Print 2016 Nov."
        },
        {
          "pmid": "24055850",
          "type": "BACKGROUND",
          "citation": "Zheng JH, Guida LA, Rower C, Castillo-Mancilla J, Meditz A, Klein B, Kerr BJ, Langness J, Bushman L, Kiser J, Anderson PL. Quantitation of tenofovir and emtricitabine in dried blood spots (DBS) with LC-MS/MS. J Pharm Biomed Anal. 2014 Jan;88:144-51. doi: 10.1016/j.jpba.2013.08.033. Epub 2013 Aug 31."
        },
        {
          "pmid": "21118913",
          "type": "BACKGROUND",
          "citation": "Anderson PL, Kiser JJ, Gardner EM, Rower JE, Meditz A, Grant RM. Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother. 2011 Feb;66(2):240-50. doi: 10.1093/jac/dkq447. Epub 2010 Nov 30."
        }
      ]
    },
    "ipdSharingStatementModule": {
      "ipdSharing": "NO"
    }
  },
  "resultsSection": {
    "participantFlowModule": {
      "groups": [
        {
          "id": "FG000",
          "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
          "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
        }
      ],
      "periods": [
        {
          "title": "Overall Study",
          "milestones": [
            {
              "type": "STARTED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "20"
                }
              ]
            },
            {
              "type": "COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "19"
                }
              ]
            },
            {
              "type": "NOT COMPLETED",
              "achievements": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                }
              ]
            }
          ],
          "dropWithdraws": [
            {
              "type": "Physician Decision",
              "reasons": [
                {
                  "groupId": "FG000",
                  "numSubjects": "1"
                }
              ]
            }
          ]
        }
      ]
    },
    "baselineCharacteristicsModule": {
      "groups": [
        {
          "id": "BG000",
          "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
          "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
        }
      ],
      "denoms": [
        {
          "units": "Participants",
          "counts": [
            {
              "groupId": "BG000",
              "value": "20"
            }
          ]
        }
      ],
      "measures": [
        {
          "title": "Age, Categorical",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "<=18 years",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Between 18 and 65 years",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "17"
                    }
                  ]
                },
                {
                  "title": ">=65 years",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Sex: Female, Male",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Female",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "5"
                    }
                  ]
                },
                {
                  "title": "Male",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "15"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Ethnicity (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "4"
                    }
                  ]
                },
                {
                  "title": "Not Hispanic or Latino",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "16"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Race (NIH/OMB)",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "categories": [
                {
                  "title": "American Indian or Alaska Native",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Asian",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Native Hawaiian or Other Pacific Islander",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                },
                {
                  "title": "Black or African American",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "16"
                    }
                  ]
                },
                {
                  "title": "White",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "1"
                    }
                  ]
                },
                {
                  "title": "More than one race",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "3"
                    }
                  ]
                },
                {
                  "title": "Unknown or Not Reported",
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "title": "Region of Enrollment",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "classes": [
            {
              "title": "United States",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "BG000",
                      "value": "20"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "outcomeMeasuresModule": {
      "outcomeMeasures": [
        {
          "type": "PRIMARY",
          "title": "Number of Subjects With Plasma HIV-1 Ribonucleic Acid (RNA) <50 Copies/ml",
          "description": "HIV viral loads will be obtained from lab reports.",
          "populationDescription": "One subject was excluded from data analysis due to early study withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Up to week 48 (End of Study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "19"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Safety (Tolerability) as Measured by the Number of Subjects Who Had a Serious Adverse Event (SAE)",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "Up to week 48 (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "20"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Intracellular TAF Levels as Measured by Dried Blood Spot",
          "description": "Fmol/punch refers to the concentration of a substance, measured in femtomoles per a specific size of a dried blood spot (DBS) punch.",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "GEOMETRIC_MEAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "Femtomole (fmol)/punch of DBS",
          "timeFrame": "12 weeks",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Tenofovir-diphosphate (TFV-DP)",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.71",
                      "lowerLimit": "1.29",
                      "upperLimit": "2.25"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Emtricitabine triphosphate (FTC-TP)",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.18",
                      "lowerLimit": "0.88",
                      "upperLimit": "1.59"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Intracellular TAF Levels as Measured by Peripheral Blood Mononuclear Cells (PBMCs)",
          "description": "pmol/10\\^6 cells refers to the amount of a particular substance (in picomoles) per one million cells",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "GEOMETRIC_MEAN",
          "dispersionType": "95% Confidence Interval",
          "unitOfMeasure": "pmol/10^6 cells",
          "timeFrame": "12 weeks",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "TFV-DP",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2.87",
                      "lowerLimit": "2.00",
                      "upperLimit": "4.12"
                    }
                  ]
                }
              ]
            },
            {
              "title": "FTC-TP",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "2.76",
                      "lowerLimit": "1.85",
                      "upperLimit": "4.12"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Renal Function as Measured by Blood Urea Nitrogen (BUN)",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mg/dL",
          "timeFrame": "24 weeks, 48 weeks (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "week 24",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "25.21",
                      "spread": "9.06"
                    }
                  ]
                }
              ]
            },
            {
              "title": "week 48",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "23.47",
                      "spread": "9.62"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Renal Function as Measured by Creatinine",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mg/dL",
          "timeFrame": "24 weeks, 48 weeks (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "week 24",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.61",
                      "spread": "0.52"
                    }
                  ]
                }
              ]
            },
            {
              "title": "week 48",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "1.57",
                      "spread": "0.52"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Renal Function as Measured by Creatinine Clearance",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mL/min",
          "timeFrame": "24 weeks, 48 weeks (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Week 24",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "58.10",
                      "spread": "15.92"
                    }
                  ]
                }
              ]
            },
            {
              "title": "week 48",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "60.68",
                      "spread": "15.78"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Renal Function as Measured by Estimated Glomerular Filtration Rate (eGFR)",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "mL/min/1.73m^2",
          "timeFrame": "24 weeks, 48 weeks (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "week 24",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "48.32",
                      "spread": "13.98"
                    }
                  ]
                }
              ]
            },
            {
              "title": "week 48",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "49.21",
                      "spread": "14.84"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "PRIMARY",
          "title": "Tacrolimus Levels",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Standard Deviation",
          "unitOfMeasure": "ng/mL",
          "timeFrame": "12 weeks, 24 weeks, 48 weeks (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6.37",
                      "spread": "1.78"
                    }
                  ]
                }
              ]
            },
            {
              "title": "week 24",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "7.97",
                      "spread": "3.29"
                    }
                  ]
                }
              ]
            },
            {
              "title": "week 48",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "6.64",
                      "spread": "2.60"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Change From Baseline CD4+ T Lymphocyte Numbers Post Renal Transplant",
          "description": "Number of CD4+ T lymphocyte counts will be obtained from lab reports",
          "populationDescription": "1 participant was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "cells/ÂµL",
          "timeFrame": "Day 1 (Baseline), Week 4, Week 12, Week 24, Week 36, Week 48 (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "256.5263",
                      "lowerLimit": "19",
                      "upperLimit": "680"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 4",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "305.8333",
                      "lowerLimit": "24",
                      "upperLimit": "1033"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "342.2105",
                      "lowerLimit": "35",
                      "upperLimit": "920"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 24",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "374.8947",
                      "lowerLimit": "38",
                      "upperLimit": "887"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 36",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "404.6667",
                      "lowerLimit": "103",
                      "upperLimit": "958"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 48 (End of Study)",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "382.4211",
                      "lowerLimit": "129",
                      "upperLimit": "1174"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Change From Baseline CD4+ T Lymphocyte Percentages Post Renal Transplant",
          "description": "CD4+ T lymphocyte percentages will be obtained from lab reports",
          "populationDescription": "1 participant was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "Percentage of CD4+ lymphocytes",
          "timeFrame": "Day 1 (Baseline), Week 4, Week 12, Week 24, Week 36, Week 48 (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Baseline",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "22.6842",
                      "lowerLimit": "6",
                      "upperLimit": "51"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 4",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "25.667",
                      "lowerLimit": "8",
                      "upperLimit": "54"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 12",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "25.7368",
                      "lowerLimit": "8",
                      "upperLimit": "53"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 24",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "27.0526",
                      "lowerLimit": "9",
                      "upperLimit": "50"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 36",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "28.1111",
                      "lowerLimit": "10",
                      "upperLimit": "56"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 48 (End of Study)",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "26.1579",
                      "lowerLimit": "10",
                      "upperLimit": "54"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Number of Subjects With Rejection of the Kidney Transplant, Post Renal Transplant",
          "description": "Data for kidney graft rejection will be extracted from biopsy confirmed rejections.",
          "populationDescription": "1 participant was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "COUNT_OF_PARTICIPANTS",
          "unitOfMeasure": "Participants",
          "timeFrame": "up to 48 weeks (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "0"
                    }
                  ]
                }
              ]
            }
          ]
        },
        {
          "type": "SECONDARY",
          "title": "Participant Satisfaction With Reduced Pill Burden and Adverse Events (Tolerability) Measured by the Health-related Quality of Life Questionnaire",
          "description": "Satisfaction will be measured by the self-reporting health-related quality of life questionnaire ranging from 0 to 6 with higher scores indicating greater satisfaction with Biktarvy.",
          "populationDescription": "One subject was excluded from data analysis due to early withdrawal.",
          "reportingStatus": "POSTED",
          "paramType": "MEAN",
          "dispersionType": "Full Range",
          "unitOfMeasure": "score on a scale",
          "timeFrame": "Week 24, Week 48 (End of study)",
          "groups": [
            {
              "id": "OG000",
              "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
              "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food."
            }
          ],
          "denoms": [
            {
              "units": "Participants",
              "counts": [
                {
                  "groupId": "OG000",
                  "value": "19"
                }
              ]
            }
          ],
          "classes": [
            {
              "title": "Week 24",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "5.85",
                      "lowerLimit": "0",
                      "upperLimit": "6"
                    }
                  ]
                }
              ]
            },
            {
              "title": "Week 48",
              "categories": [
                {
                  "measurements": [
                    {
                      "groupId": "OG000",
                      "value": "5.89",
                      "lowerLimit": "0",
                      "upperLimit": "6"
                    }
                  ]
                }
              ]
            }
          ]
        }
      ]
    },
    "adverseEventsModule": {
      "frequencyThreshold": "0",
      "timeFrame": "Up to week 48 (End of study)",
      "eventGroups": [
        {
          "id": "EG000",
          "title": "Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF)",
          "description": "Participants receive a BIC/F/TAF tablet orally once daily with or without food.",
          "deathsNumAffected": 0,
          "deathsNumAtRisk": 20,
          "seriousNumAffected": 1,
          "seriousNumAtRisk": 20,
          "otherNumAffected": 5,
          "otherNumAtRisk": 20
        }
      ],
      "seriousEvents": [
        {
          "term": "Anaphylaxis",
          "organSystem": "Immune system disorders",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 1,
              "numAtRisk": 20
            }
          ]
        }
      ],
      "otherEvents": [
        {
          "term": "Loose Stool/ Diarrhea",
          "organSystem": "Gastrointestinal disorders",
          "assessmentType": "SYSTEMATIC_ASSESSMENT",
          "stats": [
            {
              "groupId": "EG000",
              "numAffected": 5,
              "numAtRisk": 20
            }
          ]
        }
      ]
    },
    "moreInfoModule": {
      "limitationsAndCaveats": {
        "description": "The sample size was not sufficient for the statistical analysis plan as written, and, therefore, only descriptive statistics can be presented for the study."
      },
      "certainAgreement": {
        "piSponsorEmployee": true
      },
      "pointOfContact": {
        "title": "Catherine Small, MD",
        "organization": "Weill Cornell Medicine",
        "email": "cbs9003@med.cornell.edu",
        "phone": "212-746-9803"
      }
    }
  },
  "documentSection": {
    "largeDocumentModule": {
      "largeDocs": [
        {
          "typeAbbrev": "Prot_SAP",
          "hasProtocol": true,
          "hasSap": true,
          "hasIcf": false,
          "label": "Study Protocol and Statistical Analysis Plan",
          "date": "2023-03-15",
          "uploadDate": "2025-06-23T12:13",
          "filename": "Prot_SAP_000.pdf",
          "size": 842363
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2025-12-02",
      "submissionTracking": {
        "firstMcpInfo": {
          "postDateStruct": {
            "date": "2025-07-16",
            "type": "ACTUAL"
          }
        }
      }
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D015658",
          "term": "HIV Infections"
        },
        {
          "id": "D006679",
          "term": "HIV Seropositivity"
        }
      ],
      "ancestors": [
        {
          "id": "D000086982",
          "term": "Blood-Borne Infections"
        },
        {
          "id": "D003141",
          "term": "Communicable Diseases"
        },
        {
          "id": "D007239",
          "term": "Infections"
        },
        {
          "id": "D015229",
          "term": "Sexually Transmitted Diseases, Viral"
        },
        {
          "id": "D012749",
          "term": "Sexually Transmitted Diseases"
        },
        {
          "id": "D016180",
          "term": "Lentivirus Infections"
        },
        {
          "id": "D012192",
          "term": "Retroviridae Infections"
        },
        {
          "id": "D012327",
          "term": "RNA Virus Infections"
        },
        {
          "id": "D014777",
          "term": "Virus Diseases"
        },
        {
          "id": "D000091662",
          "term": "Genital Diseases"
        },
        {
          "id": "D000091642",
          "term": "Urogenital Diseases"
        },
        {
          "id": "D007153",
          "term": "Immunologic Deficiency Syndromes"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        }
      ]
    },
    "interventionBrowseModule": {
      "meshes": [
        {
          "id": "C000654125",
          "term": "bictegravir, emtricitabine, tenofovir alafenamide, drug combination"
        }
      ]
    }
  },
  "hasResults": true
}